/PRNewswire/ Pomerantz LLP is investigating claims on behalf of investors of Curis, Inc. ("Curis" or the "Company") (NASDAQ: CRIS). Such investors are.
/PRNewswire/ Pomerantz LLP is investigating claims on behalf of investors of Curis, Inc. ("Curis" or the "Company") (NASDAQ: CRIS). Such investors are.
/PRNewswire/ Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today.